MTAK - Microwave Therapy for Actinic Keratosis

MTAK - 光化性角化病的微波疗法

• 批准号: 103352
• 金额: $ 36.01万
• 依托单位: EMBLATION LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103352
• 关键词: MTAK; Microwave; Therapy; Actinic; Keratosis

It is estimated that 1 in 3 people over 60 years old in the UK has at least one actinic keratosis (AK) lesion. Actinic keratoses are the first appearance of a non-melanoma skin cancer. With a deficit of more than 200 dermatologists in the UK, the ability to diagnose and treat is being diminished. Up to 25% of GP workload is skin based and with an ageing population the crisis in dermatology needs treatments that are effective, decentralised and time efficient. Existing treatments fail to balance effectiveness, side effects and cost.Emblation wish to repurpose a portable microwave platform for use in treating AK. Already a highly effective treatment for plantar warts, through a combined destructive and immune response effect, the potential to treat AK needs to be explored. Measurements of the physical properties of AK will also be taken in order to adapt and develop the current product’s hand piece antenna (the part applied to the skin). Studies in a lab will help determine the dose to treat AK cells on humans in a small trial, in addition to investigating the healing mechanisms at play. The results and experimental data will provide a starting point for a Randomised Control Trial (RCT) after the project. An RCT is high risk and cost without this project .

据估计，在英国，60岁以上的人中有三分之一至少有一种光化性角化病（AK）病变。光化性角化病是一种非黑色素瘤皮肤癌的首发表现。由于英国缺乏200多名皮肤科医生，诊断和治疗的能力正在下降。高达25%的全科医生工作量是基于皮肤的，随着人口老龄化，皮肤病学危机需要有效、分散和高效的治疗。现有的治疗方法无法平衡疗效、副作用和成本。我们希望重新设计一种便携式微波平台，用于治疗AK。通过结合破坏性和免疫反应效应，已经是一种非常有效的治疗足底疣的方法，治疗AK的潜力需要探索。为了适应和开发当前产品的手持天线（应用于皮肤的部分），还将对AK的物理特性进行测量。实验室的研究将有助于确定在小型试验中治疗人类AK细胞的剂量，此外还将研究起作用的愈合机制。结果和实验数据将为项目结束后的随机对照试验（RCT）提供起点。没有这个项目，随机对照试验的风险和成本都很高。